Biotech Stocks
The latest news, updates and opinions on Biotech Stocks from the expert team here at MoneyWeek
-
Share tips 2026: this week’s top stock picksShare tips Share tips 2026: MoneyWeek’s roundup of the top stock picks this week – here’s what the experts think you should buy.
By MoneyWeek Last updated
Share tips -
The golden age of biotechnology – and why you should investSponsor Content Created With RTW Biotech Opportunities
RTW Bio offers exposure to three cutting-edge advancements in biotechnology at an attractive discount to the underlying portfolio’s valuation.
By MoneyWeek Published
-
Three compelling healthcare stocksThree healthcare stocks, as picked by Trevor Polischuk, lead manager at the Worldwide Healthcare Trust.
By Trevor Polischuk Published
-
Where to find healthy profits in biotechPodcast Biotech has been misunderstood as inherently risky for years. But that is no longer the case.
By Daniel Hilton Published
Podcast -
Biotech's future looks bright – the best investments to buyBiotechnology companies are coming out of a dark period for the industry. Why has the tide turned, and is now a good time to buy in?
By David Prosser Published
-
Dr Douglas Williams: new drugs and AI will fuel the biotech boomHealthcare veteran Dr Douglas Williams on the effect on the biotech sector of US political upheaval, and the prospect of major new treatments
By Dr Matthew Partridge Published
-
Healthcare can only gain from AI – where to investAI will lower healthcare costs and improve research, while demand is unlikely to be harmed. Here are some of the best ways to invest
By Rupert Hargreaves Published
-
Biotech’s recovery is underway. And investors are about to miss itSponsor Content Created With RTW Investments
Deal activity is accelerating, a new generation of cancer treatments is reaching patients and biotech is becoming profitable. The case for the sector in 2026 is stronger than it was a year ago.
By MoneyWeek Published
-
How to profit from an ageing populationAgeing populations could create an explosion in healthcare costs for society. But with new treatments, there are opportunities for canny investors
By Dr Matthew Partridge Published
